Pharmacological interventions for weight loss in the context of OSA have gained increasing attention, particularly with the emergence of incretin-based therapies such as GLP-1 RAs and dual agonists like tirzepatide. This evidence concerns the gene GCG and obstructive sleep apnea syndrome.